Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Xiidra Buy Looks Even Pricier With File Pulled In EU

EMA Questions Efficacy Of Eye Drop

Executive Summary

A year after inking a multi-billion dollar deal to get hold of the Takeda eye drop, Novartis has given up on getting approval for Xiidra in Europe with the EMA unconvinced about the therapy's efficacy.

You may also be interested in...



COVID-19 Clouds Eye Drug Sales at Novartis

Despite the impact from COVID-19, Novartis performed strongly in the second quarter "demonstrating resilience and agility of our associates and operations," according to CEO Vas Narasimhan. However, there is cause for concern at its ophthalmogy business and those problems are certainly not all down to coronavirus.  

EMA Unconvinced By Xiidra Dry Eye Data

The data package used to secure the US approval of Novartis's dry eye drug Xiidra (lifitegrast) was not enough to convince European regulators and experts in the field of eye diseases that the treatment should be sold in the EU.

Takeda Sheds More Non-Core Assets, Employees In $670m Orifarm Deal

Danish firm picks up portfolio and manufacturing sites, along with around 600 employees.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1123738

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel